Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for chronic schizophrenia
IRCT20090117001556N126Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of adalimumab in schizophrenia (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Severity of schizophrenia. Started Jun 2020; status: completed.
02
Drugs
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20090117001556N126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N126.